title: [Ginsenosides and dexamethasone in managing the liver injury and renal function after transcatheter arterial chemoembolization for hepatic carcinoma patient].
abstract: OBJECTIVE
  To observe the protective effect of ginsenosides (GS) or low dose of glucocorticoid dexamethasone (Dex) alone or combined in managing the liver injury and renal function after transcatheter arterial chemoembolization (TACE).
  
  
  METHODS
  120 patients with primary liver carcinoma were randomly divided into four groups (A, B, C, D) with 30 patients in each. Group A was treated with placebo; group B with Dex; group C with GS and group D with Dex plus GS. The changes in liver and renal function after TACE were observe according to the WHO criteria for side effects of anti-cancer drug.
  
  
  RESULTS
  Compared with group A, Dex combined with GS was able to reduce the level of TB, ALT/AST, BUN and Child-grade, which significantly protected the liver and kidney (P < 0. 05). However, Dex or GS alone could also improve some parameters of liver and renal function after TACE (P < 0.05).
  
  
  CONCLUSIONS
  Dex combined with GS is effective in managing the liver injury and renal function after transcatheter arterial
authors.affiliation: Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.
authors.forename: Ying-lu
authors.initials: YL
authors.lastname: Feng
authors.forename: Chang-quan
authors.initials: CQ
authors.lastname: Ling
authors.forename: Zhe
authors.initials: Z
authors.lastname: Chen
authors.forename: Bai
authors.initials: B
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Gu
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001806:Blood Urea Nitrogen; D016461:Chemoembolization, Therapeutic / Q000009:adverse effects / Q000379:methods*; D003404:Creatinine / Q000097:blood; D003907:Dexamethasone / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D036145:Ginsenosides / Q000494:pharmacology / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage; D007668:Kidney / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008107:Liver Diseases / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D008113:Liver Neoplasms / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D019772:Topotecan / Q000008:administration & dosage
chemical_list: D036145:Ginsenosides; D005938:Glucocorticoids; D015251:Epirubicin; D019772:Topotecan; D003907:Dexamethasone; D007459:Iodized Oil; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin; D005472:Fluorouracil